Shots:
- EirGenix has entered into a strategic collaboration and non-exclusive licensing agreement with Transcenta for its Highly Intensified Continuous Bioprocessing (HiCB) platform
- Under the agreement, Transcenta will grant EirGenix a non-exclusive license to its HiCB platform, incl. continuous perfusion & integrated hybrid continuous purification process technologies, as well as documentation, know-how & regulatory support to advance EirGenix’s biologics development, manufacturing & CDMO services
- In return, Transcenta will receive substantial upfront & milestone payments, along with future royalties tied to the commercial use of the licensed technologies
Ref: Globenewswire | Image: EirGenix & Transcenta | Press Release
Related News: EirGenix Enters ~$152M Licensing Deal with Sandoz to Commercialize EG1206A (Biosimilar, Perjeta)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
